Programmed Death Receptor-1 Blocking Antibody [EPC]

102073 reported adverse events

Drugs of this class: ATEZOLIZUMAB DOSTARLIMAB NIVOLUMAB PEMBROLIZUMAB

These side effects are most commonly reported by patients taking drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 11842
1 DEATH 11180
2 DIARRHOEA 4760
3 PYREXIA 4346
4 FATIGUE 4277
5 OFF LABEL USE 4217
6 DYSPNOEA 3237
7 NAUSEA 3055
8 PRODUCT USE IN UNAPPROVED INDICATION 3048
9 RASH 3018
See all common reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]

Drugs of the Programmed Death Receptor-1 Blocking Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 IMMUNE-MEDIATED HEPATIC DISORDER 202 0.9712
1 IMMUNE-MEDIATED THYROIDITIS 59 0.9672
2 IMMUNE-MEDIATED HYPOTHYROIDISM 95 0.9500
3 IMMUNE-MEDIATED CHOLANGITIS 37 0.9487
4 IMMUNE-MEDIATED PANCREATITIS 65 0.9420
5 IMMUNE-MEDIATED MYOCARDITIS 154 0.9333
6 IMMUNE-MEDIATED DERMATITIS 48 0.9057
7 IMMUNE-MEDIATED ARTHRITIS 67 0.8933
8 IMMUNE-MEDIATED ENCEPHALITIS 58 0.8788
9 IMMUNE-MEDIATED HYPOPHYSITIS 29 0.8788
See all enriched reactions for Programmed Death Receptor-1 Blocking Antibody [EPC]